WO2026058187 - LONG-ACTING PARENTERAL FORMULATIONS OF TOFACITINIB AND TOFACITINIB SALTS
National phase entry is expected:
Publication Number
WO/2026/058187
Publication Date
19.03.2026
International Application No.
PCT/IB2025/059131
International Filing Date
11.09.2025
Title **
[English]
LONG-ACTING PARENTERAL FORMULATIONS OF TOFACITINIB AND TOFACITINIB SALTS
[French]
FORMULATIONS PARENTÉRALES À ACTION PROLONGÉE DE TOFACITINIB ET DE SELS DE TOFACITINIB
Applicants **
LEIUTIS PHARMACEUTICALS LLP
Inventors
KOCHERLAKOTA, Chandrashekhar
BANDA, Nagaraju
RAMREDDY, Srividya
PULLAGURA, Naga Udaya Sankar
Priority Data
202441068633
11.09.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1954 | |
| EPO | Filing, Examination, Granting | 11587 | |
| Japan | Filing, Examination, Granting | 1991 | |
| South Korea | Filing, Examination, Granting | 1719 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,991
Contact Us
Abstract[English]
The present invention relates to long-acting parenteral formulations of tofacitinib comprising of tofacitinib or its fatty acid salts along with pharmaceutically acceptable excipients.[French]
La présente invention concerne des formulations parentérales à action prolongée de tofacitinib comprenant du tofacitinib ou ses sels d'acides gras ainsi que des excipients pharmaceutiquement acceptables.